Viking Therapeutics is trading at $24.29, down 4.24% in pre-market after reporting a $1.55 per-share loss, missing the $1.06 analyst estimate. - Net loss widened to $183.2 million; R&D expense rose to $166.8 million as obesity-trial programs expanded. - Quarter-end cash was $960 million, and maintenance-dosing results were positive, but neither offset the earnings reaction. - Shares continued declining from the October 20 close of $26.71; no pre-market volume data was provided.